StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT – Free Report) in a report released on Friday morning. The brokerage issued a hold rating on the stock.
Separately, JMP Securities reissued a “market outperform” rating and set a $10.00 price target on shares of DBV Technologies in a research report on Friday, January 10th.
View Our Latest Stock Report on DBV Technologies
DBV Technologies Stock Down 6.5 %
Institutional Investors Weigh In On DBV Technologies
A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent reporting period. 71.74% of the stock is owned by hedge funds and other institutional investors.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.
Featured Stories
- Five stocks we like better than DBV Technologies
- CD Calculator: Certificate of Deposit Calculator
- How to Build the Ultimate Everything ETF Portfolio
- 5 discounted opportunities for dividend growth investors
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What Investors Need to Know About Upcoming IPOs
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.